$5.71
+0.06 (+1.06%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where EDSA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 3 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, JANE STREET GROUP, LLC, TWO SIGMA INVESTMENTS, LP) · FINRA short interest 3.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19NCT04401475Mortality rate at Day 28 from IP administration.Randomized · Triple-masked · Treatment | Phase 2/3 | Suspendedsponsor's stated reason: Edesa has made the decision to suspend this study solely for business reasons. The study stop is not related to any safety concerns of the product. | Biological: SOC plus 15mg/kg EB05 IV · Other: SOC plus Placebo IV | COVID-19, ARDS | 644 | Dec 2024 | 2024-11-14 |
| Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact DermatitisNCT03680131Mean percent change from baseline in the Contact Dermatitis Severity Index (CDSI)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: EB01 Cream Placebo, EB01 Cream 0.2%, EB01 Cream 1.0%, EB01 Cream 2.0% | Allergic Contact Dermatitis | 211 | 2022-09-21actual | 2024-11-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19